SAB Biotherapeutics (SABS) Return on Sales (2021 - 2025)
Historic Return on Sales for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 278.74%.
- SAB Biotherapeutics' Return on Sales rose 3088600.0% to 278.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 681.11%, marking a year-over-year increase of 7112400.0%. This contributed to the annual value of 31.72% for FY2024, which is 128700.0% down from last year.
- As of Q3 2025, SAB Biotherapeutics' Return on Sales stood at 278.74%, which was up 3088600.0% from 152.04% recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Return on Sales registered a high of 278.74% during Q3 2025, and its lowest value of 86.69% during Q4 2024.
- Moreover, its 5-year median value for Return on Sales was 1.97% (2022), whereas its average is 13.47%.
- In the last 5 years, SAB Biotherapeutics' Return on Sales crashed by -797100bps in 2023 and then soared by 3088600bps in 2025.
- Quarter analysis of 5 years shows SAB Biotherapeutics' Return on Sales stood at 1.04% in 2021, then crashed by -248bps to 3.63% in 2022, then crashed by -1963bps to 74.94% in 2023, then dropped by -16bps to 86.69% in 2024, then soared by 422bps to 278.74% in 2025.
- Its Return on Sales stands at 278.74% for Q3 2025, versus 152.04% for Q2 2025 and 154.95% for Q1 2025.